Overcoming the challenges of tissue delivery for oligonucleotide therapeutics

内吞循环 寡核苷酸 内体 细胞生物学 核糖核酸 内化 生物 细胞 DNA 化学 基因 内吞作用 生物化学
作者
Tufan Gökirmak,Mehran Nikan,Svenja Wiechmann,Thazha P. Prakash,Michael Tanowitz,Punit P. Seth
出处
期刊:Trends in Pharmacological Sciences [Elsevier BV]
卷期号:42 (7): 588-604 被引量:61
标识
DOI:10.1016/j.tips.2021.04.010
摘要

Synthetic therapeutic oligonucleotides (STOs) target genes and gene products by utilizing endogenous endonucleases for the degradation of cellular RNA, RNA maturation pathways by modulating splicing, and protein translation by sterically blocking the access of ribosomal machinery to mRNA. STOs cross at least two phospholipid bilayers, plasma, and endosomal membranes, to reach their biological targets, mRNA and DNA inside cells. They enter the cell through receptor-mediated endocytic uptake and escape endosomal compartments to access the cytoplasm and/or nucleus, where they exert pharmacological effects through different antisense mechanisms. Backbone and sugar modifications improve the drug properties of STOs by increasing their metabolic stability and affinity for plasma proteins to reduce glomerular filtration and urinary excretion, thereby facilitating distribution to peripheral tissues. Subsequent interactions with cell surface proteins promotes cellular internalization by endocytic pathways. Next-generation oligonucleotide drugs are targeted therapeutics conjugated to endogenous or exogenous ligands for cell-surface receptors expressed in specific cell types or tissues. Givosiran (Givlaari®) is the first ligand conjugated STO developed by Alnylam for the treatment of adults with acute hepatic porphyria. Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing to exert their pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. In this review, we present the recent advances in this field with a specific focus on antisense oligonucleotides (ASOs) and siRNA therapeutics. Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing to exert their pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. In this review, we present the recent advances in this field with a specific focus on antisense oligonucleotides (ASOs) and siRNA therapeutics. chemically modified, short, single-stranded oligonucleotides (typically 12–20 mer) that bind to their target RNA by Watson-Crick base-pairing principles and modulate expression of their target mRNA by multiple antisense mechanisms. routes of drug administration where the compound is directly delivered into the tissue of interest. These methods of administration bypass tissue barriers such as the blood–brain barrier (BBB) and blood–retinal barrier and reduce exposure to systemic tissues. Examples of local delivery methods include intrathecal or intraocular injections for delivery to the CNS or the eye, and aerosol delivery to the lungs. an endonuclease that specifically cleaves the RNA strand of a DNA–RNA hybrid. ASOs bind to target mRNA through complementary base pairing, recruiting RNaseH1 that leads to degradation of the target mRNA, thus preventing the translation of mRNA into protein. an siRNA or miRNA-directed endonuclease that is composed of multiprotein complex, which incorporates one strand of a siRNA or miRNA duplex for interaction with complementary mRNA sequence. Upon activation, one of the proteins in the complex (Argonaute 2), cleaves the target mRNA. double-stranded short RNA or modified duplexes that mediate targeted mRNA degradation through RISC complex formation. routes of drug administration where the compound is directly delivered into the blood stream to access tissues. Systemic delivery methods for synthetic therapeutic oligonucleotides (STO) include intravenous, intramuscular, and subcutaneous injections.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
包李完成签到,获得积分10
2秒前
科研小虫完成签到,获得积分10
5秒前
nianxunxi完成签到,获得积分10
6秒前
CipherSage应助一颗椰子糖耶采纳,获得10
6秒前
7秒前
慕青应助叶子采纳,获得10
8秒前
9秒前
无花果应助漂亮白枫采纳,获得10
11秒前
dormraider完成签到,获得积分10
11秒前
12秒前
13秒前
15秒前
ppwl完成签到,获得积分10
16秒前
16秒前
万能图书馆应助bbh采纳,获得10
17秒前
星辰大海应助bbh采纳,获得10
17秒前
Lucas应助bbh采纳,获得10
17秒前
希望天下0贩的0应助bbh采纳,获得10
17秒前
充电宝应助bbh采纳,获得10
17秒前
所所应助bbh采纳,获得10
17秒前
完美世界应助bbh采纳,获得10
17秒前
SciGPT应助bbh采纳,获得10
17秒前
酷波er应助bbh采纳,获得10
17秒前
爱宝乐宝福宝应助bbh采纳,获得10
17秒前
19秒前
20秒前
好消息发布了新的文献求助20
21秒前
21秒前
一直向前发布了新的文献求助10
24秒前
如意的泥猴桃完成签到,获得积分10
26秒前
土拨鼠完成签到 ,获得积分10
26秒前
27秒前
科目三应助林好事采纳,获得10
27秒前
叶子完成签到,获得积分10
27秒前
27秒前
Newt发布了新的文献求助10
28秒前
30秒前
李健应助青黛采纳,获得10
31秒前
小四发布了新的文献求助10
34秒前
Sky36001发布了新的文献求助20
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989797
求助须知:如何正确求助?哪些是违规求助? 3531914
关于积分的说明 11255516
捐赠科研通 3270597
什么是DOI,文献DOI怎么找? 1805008
邀请新用户注册赠送积分活动 882181
科研通“疑难数据库(出版商)”最低求助积分说明 809190